Core Viewpoint - Green Leaf Pharmaceutical (02186) announced a share transfer agreement involving its subsidiary, Nanjing Green Leaf, where an investor will transfer 25% of its equity to Nanjing Xinshi for RMB 1.086 billion, aimed at securing financing and support for the company’s operations in the oncology sector [1][2]. Group 1: Share Transfer Agreement - The investor, Shenzhen Green Leaf Private Equity Investment Fund, will transfer 25% of its stake in Nanjing Green Leaf to Nanjing Xinshi for RMB 1.086 billion [1]. - Nanjing Xinshi, a limited partnership, will hold approximately 33.2% of the partnership interests after a previous investment of RMB 200 million by Shandong Green Leaf [1]. - The remaining interests in Nanjing Xinshi are held by China Cinda (66.4%) and other partners [1]. Group 2: Financing and Obligations - Following the share transfer, Nanjing Xinshi is expected to secure bank financing of up to RMB 648 million, with guarantees provided by Shandong Green Leaf and Shenzhen Green Leaf [2]. - Nanjing Xinshi is required to make semi-annual distributions to China Cinda as per the partnership agreement [2]. - The agreements include options for Shandong Green Leaf to acquire interests from China Cinda and other partners under specified conditions [2]. Group 3: Business Focus - Nanjing Green Leaf and its subsidiaries primarily engage in the production and sale of pharmaceuticals, focusing on oncology treatments [2].
绿叶制药：南京信石拟10.86亿元收购南京绿叶25%股权